IRONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Disc Medicine, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$78.93+22.09 (+38.86%)
Close on Oct 19, 2026
- Market cap
- $3.05B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
43M of 38M shares
Institutional holders
216
39 new, 22 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 92 sales
Net sold $106.52M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 4,875,473 | 12.80% | 13G (passive) amendment | Jun 30, 2026 |
| Len Blavatnik | 3,762,507 | 10.80% | 13D (active) amendment | Feb 27, 2025 |
| Abigail P. Johnson | 3,224,381 | 9.30% | 13G (passive) amendment | Mar 31, 2025 |
| Access Industries Holdings LLC | 3,018,460 | 8.00% | 13D (active) amendment | Oct 20, 2025 |
| Wellington Management Company LLP | 2,343,499 | 6.40% | 13G (passive) | Mar 31, 2025 |
| Peter Kolchinsky | 2,228,924 | 5.90% | 13G (passive) | Dec 30, 2025 |
| BlackRock, Inc. | 1,851,171 | 6.20% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IRON | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 4,894,473 | 12.75% | $357.98M | −692,421 | 0.02% |
| BlackRock, Inc. | 2,467,899 | 6.43% | $180.50M | +194,068 | 0.00% |
| Ra Capital Management, L.P. | 2,450,221 | 6.38% | $179.21M | – | 1.56% |
| JPMorgan Chase & Co | 1,875,795 | 4.89% | $139.87M | +504,315 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 1,875,399 | 4.88% | $137.17K | +326,049 | 0.01% |
| Wellington Management Group Llp | 1,741,351 | 4.54% | $127.36M | +5,975 | 0.02% |
| State Street Corp | 1,648,836 | 4.29% | $120.60M | −49,408 | 0.00% |
| Vestal Point Capital, LP | 1,550,000 | 4.04% | $113.37M | +850,000 | 2.65% |
| Atlas Venture Life Science Advisors, LLC | 1,513,875 | 3.94% | $110.72M | – | 12.56% |
| Vanguard Capital Management LLC | 1,369,027 | 3.57% | $100.13M | −6,403 | 0.00% |
| Frazier Life Sciences Management, L.P. | 1,354,852 | 3.53% | $99.09M | – | 2.16% |
| TCG Crossover Management, LLC | 1,341,862 | 3.50% | $98.14M | – | 2.36% |
| Bvf Inc/Il | 1,153,612 | 3.00% | $84.38M | −118,700 | 2.16% |
| Woodline Partners LP | 958,281 | 2.50% | $70.09M | – | 0.22% |
| Siren, L.L.C. | 888,401 | 2.31% | $64.98M | −100,000 | 1.31% |
| Logos Global Management LP | 875,000 | 2.28% | $64.00M | +315,000 | 2.76% |
| Opaleye Management Inc. | 855,000 | 2.23% | $62.53M | +434,000 | 5.66% |
| Geode Capital Management, LLC | 789,724 | 2.06% | $57.77M | +45,502 | 0.00% |
| Assenagon Asset Management S.A. | 768,316 | 2.00% | $56.19M | +222,069 | 0.04% |
| Deerfield Management Company, L.P. (Series C) | 657,000 | 1.71% | $48.05M | – | 0.50% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 216 | 43M | 100.0% | 39 / 77 | 62 / 22 | 5M | 3M |
| Q1 2026 | 203 | 42M | 100.0% | 47 / 81 | 44 / 38 | 9M | 4M |
| Q4 2025 | 197 | 38M | 99.7% | 42 / 86 | 48 / 11 | 8M | 5M |
| Q3 2025 | 168 | 35M | 91.1% | 26 / 62 | 44 / 9 | 5M | 5M |
| Q2 2025 | 151 | 34M | 88.8% | 26 / 68 | 37 / 31 | 4M | 3M |
| Q1 2025 | 157 | 33M | 86.4% | 27 / 74 | 31 / 21 | 9M | 2M |
| Q4 2024 | 152 | 27M | 69.2% | 37 / 49 | 45 / 15 | 4M | 5M |
| Q3 2024 | 132 | 27M | 71.6% | 25 / 58 | 28 / 12 | 4M | 3M |
| Q2 2024 | 121 | 29M | 74.7% | 29 / 55 | 30 / 37 | 10M | 4M |
| Q1 2024 | 130 | 23M | 59.1% | 31 / 58 | 28 / 12 | 4M | 2M |
| Q4 2023 | 112 | 20M | 52.9% | 32 / 40 | 29 / 10 | 4M | 4M |
| Q3 2023 | 91 | 20M | 51.9% | 19 / 39 | 19 / 18 | 4M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of IRON | Value | % of fund | As of |
|---|---|---|---|---|---|
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,889,838 | 4.92% | $131.48M | 0.05% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 970,661 | 2.53% | $70.99M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 958,601 | 2.50% | $70.11M | 0.65% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 739,640 | 1.93% | $54.10M | 0.07% | Jun 30, 2026 |
| JPMorgan Mid Cap Growth Fund | 647,794 | 1.69% | $47.38M | 0.36% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 566,760 | 1.48% | $41.45M | 0.28% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 454,774 | 1.18% | $31.64M | 0.60% | May 31, 2026 |
| Select Health Care Portfolio | 450,000 | 1.17% | $31.31M | 0.54% | May 31, 2026 |
| Eventide Healthcare & Life Sciences Fund | 395,235 | 1.03% | $28.91M | 1.62% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 375,603 | 0.98% | $27.47M | 0.28% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 366,949 | 0.96% | $26.84M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 309,253 | 0.81% | $23.81M | 0.07% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund | 278,384 | 0.73% | $21.44M | 0.24% | Jul 31, 2026 |
| JPMorgan Small Cap Growth Fund | 274,234 | 0.71% | $20.06M | 0.77% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 261,158 | 0.68% | $19.10M | 0.12% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John D. Quisel | Chief Executive Officer, Director | 262,064 | 0.68% | Sep 16, 2026 |
| Jonathan Yen-Wen Yu | Chief Operating Officer | 63,120 | 0.16% | Aug 26, 2026 |
| Rahul Khara | Chief Legal Officer | 57,324 | 0.15% | Aug 7, 2026 |
| Jean M. Franchi | Chief Financial Officer | 64,333 | 0.17% | Apr 15, 2026 |
| William Jacob Savage | Chief Medical Officer | 81,680 | 0.21% | Apr 15, 2026 |
| Pamela Stephenson | Chief Commercial Officer | 80,998 | 0.21% | Feb 17, 2026 |
| Kevin Bitterman | Director | 326,002 | 0.85% | Sep 15, 2026 |
| Georges Gemayel | Director | – | – | Jun 23, 2026 |
| Nadim Ahmed | Director | – | – | Jun 23, 2026 |
| Mark Chin | Director | – | – | Jun 23, 2026 |
| William Richard White | Director | 0 | – | Jun 23, 2026 |
| Liam Ratcliffe | Director | – | – | Jun 23, 2026 |
| Donald William Nicholson | Director | 15,332 | 0.04% | Jun 23, 2026 |
| Mona Ashiya | Director | 186,541 | 0.49% | Jun 13, 2025 |
| Genesis GP LLC OrbiMed | Director | 941,569 | 2.45% | Mar 26, 2025 |
| Advisors Llc Orbimed | Director | 5,798,532 | 15.10% | Mar 26, 2025 |
| Capital GP VIII LLC OrbiMed | Director | – | – | Mar 26, 2025 |
| Capital GP VI LLC OrbiMed | Director | 187,297 | 0.49% | Mar 26, 2025 |
| Industries Holdings LLC Access | 10% owner | 3,558,426 | 9.27% | Oct 24, 2025 |
| Dmi Llc Ai | 10% owner | 2,814,379 | 7.33% | Oct 24, 2025 |
| Access Industries Management, Llc | 10% owner | 3,141,759 | 8.18% | Oct 24, 2025 |
| Len Blavatnik | 10% owner | – | – | Oct 24, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John D. Quisel Chief Executive Officer, Director | Sep 15, 2026 | Option exercise | +36,000 | $1.01 | $36.36K | 262,064 |
| Kevin Bitterman Director | Sep 11, 2026 | Option exercise | +7,136 | $45.69 | $326.04K | 7,136 |
| Kevin Bitterman Director | Sep 11, 2026 | Option exercise | +10,000 | $38.85 | $388.50K | 17,136 |
| Kevin Bitterman Director | Sep 11, 2026 | Sale | −27,136 | $70.11 | $1.90M | 0 |
| Kevin Bitterman Director | Sep 11, 2026 | Option exercise | +10,000 | $50.86 | $508.60K | 27,136 |
| Kevin Bitterman Director | Sep 4, 2026 | Sale(10b5-1 plan) | −759 | $79.96 | $60.69K | 312,230 |
| Kevin Bitterman Director | Sep 4, 2026 | Sale(10b5-1 plan) | −18 | $79.96 | $1.44K | 13,427 |
| Kevin Bitterman Director | Sep 4, 2026 | Sale(10b5-1 plan) | −912 | $79.96 | $72.92K | 318,866 |
| Kevin Bitterman Director | Sep 3, 2026 | Sale(10b5-1 plan) | −2,339 | $79.98 | $187.07K | 312,989 |
| Kevin Bitterman Director | Sep 3, 2026 | Sale(10b5-1 plan) | −2,810 | $79.98 | $224.74K | 319,778 |
| Kevin Bitterman Director | Sep 3, 2026 | Sale(10b5-1 plan) | −54 | $79.98 | $4.32K | 13,445 |
| Kevin Bitterman Director | Sep 2, 2026 | Sale(10b5-1 plan) | −511 | $80.17 | $40.97K | 13,501 |
| Kevin Bitterman Director | Sep 2, 2026 | Sale(10b5-1 plan) | −2 | $80.98 | $162 | 13,499 |
| Kevin Bitterman Director | Sep 2, 2026 | Sale(10b5-1 plan) | −9 | $80.98 | $729 | 315,328 |
| Kevin Bitterman Director | Sep 2, 2026 | Sale(10b5-1 plan) | −10 | $80.98 | $810 | 322,588 |
| Kevin Bitterman Director | Sep 2, 2026 | Sale(10b5-1 plan) | −22,090 | $80.17 | $1.77M | 315,337 |
| Kevin Bitterman Director | Sep 2, 2026 | Sale(10b5-1 plan) | −26,542 | $80.17 | $2.13M | 322,598 |
| Kevin Bitterman Director | Sep 1, 2026 | Sale(10b5-1 plan) | −1 | $79.95 | $80 | 14,012 |
| Kevin Bitterman Director | Sep 1, 2026 | Sale(10b5-1 plan) | −58 | $79.95 | $4.64K | 337,427 |
| Kevin Bitterman Director | Sep 1, 2026 | Sale(10b5-1 plan) | −70 | $79.95 | $5.60K | 349,140 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Aug 25, 2026 | Option exercise | +8,796 | $13.50 | $118.75K | 63,120 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Aug 25, 2026 | Sale(10b5-1 plan) | −8,796 | $83.12 | $731.12K | 54,324 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Aug 24, 2026 | Option exercise | +300 | $13.50 | $4.05K | 54,624 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Aug 24, 2026 | Sale(10b5-1 plan) | −300 | $82.53 | $24.76K | 54,324 |
| John D. Quisel Chief Executive Officer, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −8,400 | $78.11 | $656.12K | 250,664 |
| John D. Quisel Chief Executive Officer, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −11,888 | $79.84 | $949.14K | 226,064 |
| John D. Quisel Chief Executive Officer, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −12,712 | $79.20 | $1.01M | 237,952 |
| John D. Quisel Chief Executive Officer, Director | Aug 17, 2026 | Option exercise | +33,000 | $13.50 | $445.50K | 259,064 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Aug 12, 2026 | Option exercise | +804 | $13.50 | $10.85K | 55,128 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Aug 12, 2026 | Sale(10b5-1 plan) | −804 | $82.64 | $66.44K | 54,324 |
| Rahul Khara Chief Legal Officer | Aug 6, 2026 | Option exercise | +5,000 | $14.69 | $73.45K | 57,324 |
| Rahul Khara Chief Legal Officer | Aug 6, 2026 | Sale(10b5-1 plan) | −5,000 | $80.00 | $400.00K | 52,324 |
| John D. Quisel Chief Executive Officer, Director | Jul 13, 2026 | Sale(10b5-1 plan) | −9,704 | $74.27 | $720.72K | 249,360 |
| John D. Quisel Chief Executive Officer, Director | Jul 13, 2026 | Option exercise | +7,416 | $13.50 | $100.12K | 259,064 |
| John D. Quisel Chief Executive Officer, Director | Jul 13, 2026 | Option exercise | +25,584 | $9.86 | $252.26K | 251,648 |
| John D. Quisel Chief Executive Officer, Director | Jul 13, 2026 | Sale(10b5-1 plan) | −6,400 | $76.05 | $486.72K | 226,064 |
| John D. Quisel Chief Executive Officer, Director | Jul 13, 2026 | Sale(10b5-1 plan) | −16,896 | $74.95 | $1.27M | 232,464 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jul 7, 2026 | Sale(10b5-1 plan) | −100 | $82.50 | $8.25K | 54,324 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jul 7, 2026 | Option exercise | +100 | $13.50 | $1.35K | 54,424 |
| Rahul Khara Chief Legal Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −1,649 | $75.00 | $123.68K | 52,173 |
| Rahul Khara Chief Legal Officer | Jun 29, 2026 | Option exercise | +1,649 | $14.69 | $24.22K | 53,822 |
| Rahul Khara Chief Legal Officer | Jun 26, 2026 | Option exercise | +851 | $14.69 | $12.50K | 53,024 |
| Rahul Khara Chief Legal Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −851 | $75.00 | $63.83K | 52,173 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −300 | $72.50 | $21.75K | 54,324 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jun 26, 2026 | Option exercise | +300 | $13.50 | $4.05K | 54,624 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −9,700 | $72.66 | $704.80K | 54,324 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jun 22, 2026 | Option exercise | +9,700 | $13.50 | $130.95K | 64,024 |
| Rahul Khara Chief Legal Officer | Jun 18, 2026 | Sale(10b5-1 plan) | −5,400 | $69.94 | $377.68K | 54,273 |
| Rahul Khara Chief Legal Officer | Jun 18, 2026 | Sale(10b5-1 plan) | −1,600 | $70.73 | $113.17K | 52,673 |
| Rahul Khara Chief Legal Officer | Jun 18, 2026 | Sale(10b5-1 plan) | −500 | $71.62 | $35.81K | 52,173 |
| Rahul Khara Chief Legal Officer | Jun 18, 2026 | Option exercise | +7,500 | $14.69 | $110.18K | 59,673 |
| John D. Quisel Chief Executive Officer, Director | Jun 18, 2026 | Sale(10b5-1 plan) | −22,927 | $69.92 | $1.60M | 237,137 |
| John D. Quisel Chief Executive Officer, Director | Jun 18, 2026 | Sale(10b5-1 plan) | −9,522 | $70.70 | $673.21K | 227,615 |
| John D. Quisel Chief Executive Officer, Director | Jun 18, 2026 | Sale(10b5-1 plan) | −1,551 | $71.61 | $111.07K | 226,064 |
| John D. Quisel Chief Executive Officer, Director | Jun 18, 2026 | Option exercise | +34,000 | $9.86 | $335.24K | 260,064 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jun 16, 2026 | Sale(10b5-1 plan) | −11,651 | $68.76 | $801.12K | 61,285 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jun 16, 2026 | Option exercise | +5,261 | $9.86 | $51.87K | 59,585 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jun 16, 2026 | Option exercise | +13,351 | $9.86 | $131.64K | 72,936 |
| Jonathan Yen-Wen Yu Chief Operating Officer | Jun 16, 2026 | Sale(10b5-1 plan) | −6,961 | $69.92 | $486.71K | 54,324 |
| Jean M. Franchi Chief Financial Officer | Apr 14, 2026 | Sale(10b5-1 plan) | −6,257 | $69.24 | $433.23K | 64,333 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| J. Bitterman Kevin Officer | Sep 11, 2026 | 27,136 | $1.90M | Sep 11, 2026 | Exercise of Options Under a Registered Plan |
| Atlas Venture Opportunity Fund I, LP Shareholder | Sep 4, 2026 | 912 | $72.39K | Sep 4, 2026 | Private Placement |
| Atlas Venture Fund X, LP Shareholder | Sep 4, 2026 | 2,212 | $175.57K | Sep 4, 2026 | Private Placement |
| Atlas Venture Fund XII, LP Shareholder | Sep 4, 2026 | 18 | $1.43K | Sep 4, 2026 | Private Placement |
| Atlas Venture Opportunity Fund II, LP Shareholder | Sep 4, 2026 | 759 | $60.24K | Sep 4, 2026 | Private Placement |
| Atlas Venture Opportunity Fund II, LP Shareholder | Sep 3, 2026 | 2,339 | $187.24K | Sep 3, 2026 | Private Placement |
| Atlas Venture Fund XII, LP Shareholder | Sep 3, 2026 | 54 | $4.32K | Sep 3, 2026 | Private Placement |
| Atlas Venture Opportunity Fund I, LP Shareholder | Sep 3, 2026 | 2,810 | $224.94K | Sep 3, 2026 | Private Placement |
| Atlas Venture Fund X, LP Shareholder | Sep 3, 2026 | 6,822 | $546.10K | Sep 3, 2026 | Private Placement |
| Atlas Venture Fund XII, LP Shareholder | Sep 2, 2026 | 513 | $40.36K | Sep 2, 2026 | Private Placement |
| Atlas Venture Opportunity Fund II, LP Shareholder | Sep 2, 2026 | 22,099 | $1.74M | Sep 2, 2026 | Private Placement |
| Atlas Venture Opportunity Fund I, LP Shareholder | Sep 2, 2026 | 26,552 | $2.09M | Sep 2, 2026 | Private Placement |
| Atlas Venture Fund X, LP Shareholder | Sep 2, 2026 | 64,460 | $5.07M | Sep 2, 2026 | Private Placement |
| Quisel John Director, Officer | Aug 17, 2026 | 33,000 | $2.60M | Aug 17, 2026 | Exercise of Stock Options |
| Khara Rahul Officer | Aug 6, 2026 | 5,000 | $394.55K | Aug 6, 2026 | Exercise of Stock Options |